EnClear Therapies Secures Seed Funding and Senior R and D Appointment
15 March 2019 - - US-based biotechnology company EnClear Therapies has secured approximately USD 2m in seed funding and that it has hired Kevin Kalish as vice president of Research and Development, the company said.

Partners in the seed financing included Thiel Capital, Bioverge, Sanford Biosciences and Christian Angermayer's Presight Capital.

Kevin Kalish has over 15 years' experience leading R and D, Program Management and Operations with Medtronic, Boston Scientific and Johnson and Johnson. Most recently he provided strategic leadership to the Transformative Solutions business unit at Medtronic.

He received his MBA from Boston College, BSE/MSE from UMass Lowell and is Program Management Professional certified.

EnClear Therapies is a Cambridge based biotechnology company developing neurology-focused, device-based systems that remove toxic proteins as therapies for the treatment of neurodegenerative diseases and provide closed loop delivery and monitoring of cerebrospinal fluids.

The company's first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy.